Take a trial of UK to unlock this pageFind out more

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed 4
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2009 2010 2011 2012 2013 2014 TTM 2015E 2016E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Last ex-div: 12th Nov, paid: 14th Jan more... Dividends
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p -14.6%

FINANCIAL BRIEF: For the six months ended 30 June 2015, GlaxoSmithKline plc revenues increased 3% to L11.51B. Net income increased from L1.32B to L8.24B. Revenues reflect Consumer Healthcare segment increase of 35% to L2.89B, Vaccines segment increase of 7% to L1.51B, Unallocated segment increase of 16% to L44M, Emerging Markets segment increase from L822M to L4.55B, USA segment increase from L1.19B to L3.79B. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 30th Jun '15) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2015
31st Dec 2016

Price Target: 14.6
(+11.51% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: +4.5% (£) (p) (p) (£) (p) (p)
Consensus Estimate
1m Change
3m Change
30 brokers Broker Consensus Trend
Broker Recommendations for GlaxoSmithKline
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 6 19 4 2

Named Brokers and Analysts
Jefferies Jeffrey Holford , Credit Suisse Jo Walton , Leerink Partners LLC Seamus Fernandez , BERNSTEIN Tim Anderson , First Global Kavita Thomas , Nomura Securities , Seymour Pierce , Panmure Gordon Mike Mitchell , Natixis Philippe Lanone Jean-Jacques Le Fur , Mirabaud Securities Nicholas Turner , Davy , Societe Generale Florent Cespedes , Berenberg Alistair Campbell , DZ Bank , Oddo Securities Sebastien Malafosse , Helvea SA Odile Rundquist , Hamburger Sparkasse (HASPA) Marco Gunther , Kepler Cheuvreux Sheela Sharma , Charles Stanley Rae Ellingham , Cenkos Securities Navid Malik , Shore Capital Stockbrokers Brian White , Bryan Garnier Eric Le Berrigaud , Morningstar, Inc. Damien Conover , Day by Day Valérie GASTALDY , Landesbank Baden-Wuerttemberg Timo Kuerschner , Liberum Naresh Chouhan , Baader Helvea Equity Research Odile Rundquist ,

Profile Summary

GlaxoSmithKline plc. (GSK) is a healthcare company that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The Company operates in two segments: Pharmaceuticals and Vaccines, and Consumer Healthcare. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases. Its human immunodeficiency virus (HIV) business is managed through ViiV Healthcare. GSK's Vaccines has a portfolio of over 30 paediatric, adolescent, adult travel vaccines. GSK's Established Products Portfolio includes over 50 off-patent products, as well as its branded generics business and other local products. The Consumer Healthcare business develops and markets products in four categories, such as wellness, oral health, nutrition and skin health. Its brands include Sensodyne, Panadol, Horlicks, Polident, Paradontax, Tums, ENO, NiQuitin/Nicorette, Abreva, Zovirax and Aquafresh. It operates in the United Kingdom, the United States, Belgium and China.

Directors: Andrew Witty (CEO) 50, Simon Dingemans (CFO) 51, Moncef Slaoui (CEX) 55, Roger Connor (CEX) , Abbas Hussain (CEX) , Shah Abbas Hussain (CEX) 49, Patrick Vallance (CEX) , Emma Walmsley (CEX) , Daniel Troy (SVP) , Claire Thomas (SVP) , Philip Hampton (NEC) 61, Manvinder Banga (NID) 59, Roy Anderson (NID) 67, Stephanie Burns (NID) 60, Stacey Cartwright (NID) 51,

No. of Employees: 98,702 No. of Shareholders: 139,535

Last Annual December 31st, 2014
Last Interim June 30th, 2015
Incorporated December 6, 1999
Public Since May 22, 1972
Shares in Issue 4,866,635,306
Free Float 4.86bn (99.8%)

Address 980 Great West Road, BRENTFORD, TW8 9GS, United Kingdom
Web http://www.gsk.com
Phone +44 20 80475000
Contact ()
Auditors PricewaterhouseCoopers LLP

GSK Share Price Performance GSKQuote
18.5  1.4%
Traded 4:57pm · Minimum 15 min delayed · NMS: 1.50k

Latest GSK News Announcements (delayed)

Upcoming GSK Events

Recent ↓
Thursday 13th August, 2015
Dividend For GSK.L
Wednesday 12th August, 2015
Dividend For GSK
Wednesday 12th August, 2015
Dividend For GSK.BA
Wednesday 29th July, 2015
Q2 2015 GlaxoSmithKline PLC Earnings Call
Wednesday 29th July, 2015
Q2 2015 GlaxoSmithKline PLC Earnings Release
Friday 19th September, 2014
GlaxoSmithKline PLC at Bank of America Merrill Lynch Global Healthcare Conference
Tuesday 9th September, 2014
GlaxoSmithKline PLC Investor and Analyst Event at the European Respiratory Society 2014
Wednesday 6th August, 2014
Dividend For GSK.BA
Wednesday 6th August, 2014
Dividend For GSK
Wednesday 23rd July, 2014
Q2 2014 GlaxoSmithKline PLC Earnings Call
Wednesday 23rd July, 2014
Q2 2014 GlaxoSmithKline PLC Earnings Release
Monday 2nd June, 2014
GlaxoSmithKline at Jefferies Global Healthcare Conference
Thursday 22nd May, 2014
GlaxoSmithKline PLC United Way of Greater Philadelphia and Southern New Jersey Issue Call for Applications Totaling $400,000 in GSK IMPACT Awards Conference Call
Thursday 22nd May, 2014
GlaxoSmithKline PLC Triangle Community Foundation Issue Call for Applications Totaling $400,000 in GSK IMPACT Awards Conference Call
Wednesday 14th May, 2014
Dividend For GSK.BA
Wednesday 14th May, 2014
Dividend For GSK
Wednesday 14th May, 2014
GlaxoSmithKline at Credit Suisse Stockholm Consumer and Healthcare IR Day
Wednesday 7th May, 2014
GlaxoSmithKline PLC Annual General Meeting

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2015.

Should you buy GSK

Access GSK Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis